Rapid structural characterization of most promising novel mAbs and vaccines
最有前途的新型单克隆抗体和疫苗的快速结构表征
基本信息
- 批准号:9057431
- 负责人:
- 金额:$ 58.47万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:AntibodiesAntigensBinding SitesComplexCryoelectron MicroscopyCrystallographyDevelopmentElectron MicroscopyEngineeringExperimental DesignsGenerationsGoalsHemagglutininHousingInfluenzaJointsMethodsModelingNegative StainingProteinsResearchResearch Project GrantsResolutionStructureTherapeuticTherapeutic antibodiesVaccine AntigenVaccine ResearchVaccinesValidationX-Ray Crystallographyanti-influenzaantibody engineeringbasecombatdesigninfluenzavirusneutralizing antibodynovelprogramsprotein complexreceptor bindingscaffoldscreeningstructural genomicstherapeutic vaccinetool
项目摘要
The Structure Core will support all three projects in this U19. The goal of our U19
research program is to use structure-based rational design to combat influenza virus
from both the therapeutic antibody and vaccine perspective. These endeavors, targeting
the receptor-binding site (RBS) on hemagglutinin (HA), require many rounds of design
and experimental validation executed in an iterative manner. Thus, the focus of this
Core is three-fold: (i) Naturally occurring antibodies from Project 1 will be studied in
complex with natural HA molecules. (ii) to solve structures of HA in complex with
engineered antibodies from Project 2 for therapeutic applications, and (iii) to solve
structures of HA engineered scaffolds in complex with known broadly neutralizing
antibodies (bnAbs) in Project 3 for vaccine applications. We will use both electron
microscopy (EM) and x-ray crystallography to accomplish these aims and generate
sufficient structural coverage to enable development of anti-influenza solutions.
Specifically, we will use electron microscopy (EM) to solve structures of HA in complex
with engineered antibodies. EM is uniquely suited to rapidly generate structural
information of protein complexes in a high-throughput manner. The information from EM
can directly inform further structural and design efforts. We will employ both negative
stain and cryo-EM methods to evaluate antibody-HA complexes at moderate and high
resolution, respectively. We will also use x-ray crystallography to solve structures of HA
and engineered HA scaffolds with antibodies. X-ray crystallography is routinely used to
reveal atomic-level details of proteins and their complexes. Using the crystal screening
capacity of The Joint Center for Structural Genomics housed at Scripps (Dr. Wilson is
the PI), we can screen large numbers of antibodies, antigens, and conjugate complexes.
We will use this pipeline to solve atomic-resolution structures of antibody-HA and
antibody-scaffold complexes.
Structure Core将支持U19中的所有三个项目。我们U19的目标是
研究计划是使用基于结构的合理设计来对抗流感病毒
从治疗性抗体和疫苗的角度来看。这些努力,目标是
血凝素(HA)上的受体结合位点(RBS)需要多轮设计
以及以迭代方式执行的实验验证。因此,这一次的重点
核心是三个方面:(I)项目1的自然产生的抗体将在#年进行研究
与天然HA分子形成复合体。(Ii)解决羟基磷灰石的复杂结构
来自项目2的用于治疗应用的工程抗体,以及(Iii)解决
具有广为人知中和作用的复合羟基磷灰石工程支架的结构
项目3中用于疫苗应用的抗体(BNAbs)。我们将使用这两个电子
显微镜(EM)和X射线结晶学来实现这些目标并产生
有足够的结构覆盖面,以便能够开发抗流感解决方案。
具体地说,我们将使用电子显微镜(EM)来解决HA在络合物中的结构
用基因工程抗体。EM是唯一适合快速生成结构的
高通量的蛋白质复合体信息。来自EM的信息
可以直接为进一步的结构和设计工作提供参考。我们将使用这两种底片
中、高度抗体-HA复合体的染色和冷冻-EM评价方法
分辨率分别为。我们还将使用x射线结晶学来解决HA的结构
并用抗体构建了HA支架。X射线结晶学通常被用来
揭示蛋白质及其复合体的原子级细节。使用水晶筛网
位于斯克里普斯的结构基因组学联合中心的能力(威尔逊博士
等电点),我们可以筛选出大量的抗体、抗原和结合物。
我们将使用这条流水线来解决抗体-HA的原子分辨结构和
抗体-支架复合体。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew Barrett Ward其他文献
Andrew Barrett Ward的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew Barrett Ward', 18)}}的其他基金
Rapid structural characterization of most promising novel mAbs and vaccines
最有前途的新型单克隆抗体和疫苗的快速结构表征
- 批准号:
8897071 - 财政年份:
- 资助金额:
$ 58.47万 - 项目类别:
相似国自然基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
- 批准号:2022J011295
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
- 批准号:30801055
- 批准年份:2008
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 58.47万 - 项目类别:
Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
- 批准号:
10083718 - 财政年份:2023
- 资助金额:
$ 58.47万 - 项目类别:
Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
- 批准号:
480030 - 财政年份:2023
- 资助金额:
$ 58.47万 - 项目类别:
Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
- 批准号:
MR/X009254/1 - 财政年份:2023
- 资助金额:
$ 58.47万 - 项目类别:
Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
- 批准号:
22KJ1758 - 财政年份:2023
- 资助金额:
$ 58.47万 - 项目类别:
Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
- 批准号:
BB/Y000927/1 - 财政年份:2023
- 资助金额:
$ 58.47万 - 项目类别:
Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
- 批准号:
10795212 - 财政年份:2023
- 资助金额:
$ 58.47万 - 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
- 批准号:
23K18249 - 财政年份:2023
- 资助金额:
$ 58.47万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
- 批准号:
10735075 - 财政年份:2023
- 资助金额:
$ 58.47万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 58.47万 - 项目类别: